Zeo ScientifiX (ZEOX) awards CMO options for 1.25M shares

Rhea-AI Filing Summary

Zeo ScientifiX, Inc. reported that Chief Medical Officer George Craig Shapiro received two stock option awards. Each grant covers 625,000 options on common stock at an exercise price of $1.67 per share, dated June 10, 2026.

One grant vests in full as of the grant date and is exercisable on a cashless basis for ten years under the 2021 Equity Incentive Plan. The other vests upon specified performance milestones and is also exercisable cashless for ten years once vested, and is described as antidilutive for future transactions issuing at least 10% of common stock on a fully diluted basis.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Shapiro George Craig

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	625,000	$0.00	--
Grant/Award	Stock Options	625,000	$0.00	--

Holdings After Transaction: Stock Options — 625,000 shares (Direct, null)

Footnotes (1)

1. Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan (the "2021 Plan"). The options vested in full as of the grant date, are exercisable on a "cashless basis" for a period of ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan. Represents the grant of stock options to purchase shares of the Issuer's common stock under the 2021 Plan. The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis" during the period commencing on the date they vest and ending ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan. The options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company's common stock outstanding on a fully diluted basis.

Key Figures

Option grant size 1: 625,000 options Option grant size 2: 625,000 options Total underlying shares: 1,250,000 shares +3 more

6 metrics

Option grant size 1 625,000 options Grant of stock options on June 10, 2026

Option grant size 2 625,000 options Second stock option grant on June 10, 2026

Total underlying shares 1,250,000 shares Combined underlying common shares for both grants

Exercise price <money>$1.67</money> per share Conversion or exercise price for each option grant

Option term 10 years Options exercisable until June 10, 2036

Grant date <date>June 10, 2026</date> Transaction date for both option awards

Key Terms

2021 Equity Incentive Plan, cashless basis, performance milestones, antidilutive, +1 more

5 terms

2021 Equity Incentive Plan financial

"Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan (the "2021 Plan")."

cashless basis financial

"The options vested in full as of the grant date, are exercisable on a "cashless basis" for a period of ten (10) years from the award date."

An agreement executed on a cashless basis lets a holder convert or exercise a security (like options, warrants, or conversion rights) without paying money upfront; instead the holder receives a smaller number of shares equal in value to what the cash would have purchased. Think of trading a coupon for fewer slices of a cake rather than handing over cash for the full slice. For investors, it affects how much ownership and dilution occur and avoids immediate cash outlays.

performance milestones financial

"The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis" during the period commencing on the date they vest."

antidilutive financial

"The options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company's common stock outstanding on a fully diluted basis."

fully diluted basis financial

"10% or more of the Company's common stock outstanding on a fully diluted basis."

A fully diluted basis counts every share that could exist if all outstanding options, warrants, convertible securities and other rights were exercised or converted into common stock, showing the maximum number of shares outstanding. For investors this matters because it spreads ownership and earnings across that larger share count, like slicing a pie into every possible piece before deciding how big each investor’s slice will be, which affects per-share value and ownership percentage.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shapiro George Craig

(Last) (First) (Middle)

3321 COLLEGE AVENUE

SUITE 246

(Street)

DAVIE FLORIDA 33314

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zeo ScientifiX, Inc. [ ZEOX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.67	06/10/2026		A(1)		625,000		06/10/2026(1)	06/10/2036	Common Stock	625,000	$0	625,000	D
Stock Options	$1.67	06/10/2026		A(2)		625,000		06/10/2026(2)	06/10/2036	Common Stock	625,000	$0	625,000	D

Explanation of Responses:

1. Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan (the "2021 Plan"). The options vested in full as of the grant date, are exercisable on a "cashless basis" for a period of ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan.

2. Represents the grant of stock options to purchase shares of the Issuer's common stock under the 2021 Plan. The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis" during the period commencing on the date they vest and ending ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan. The options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company's common stock outstanding on a fully diluted basis.

	/s/ George Craig Shapiro	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider activity did Zeo ScientifiX (ZEOX) report for its CMO?

Zeo ScientifiX reported stock option grants to its Chief Medical Officer. On June 10, 2026, George Craig Shapiro received two option awards under the 2021 Equity Incentive Plan, representing equity-based compensation rather than open-market share purchases or sales.

How many Zeo ScientifiX (ZEOX) shares are covered by the new option grants?

The grants cover options on a total of 1,250,000 shares. The Form 4 shows two separate stock option awards, each for 625,000 underlying shares of common stock, providing substantial potential future equity exposure tied to Shapiro’s role at the company.

What are the exercise price and term of the new Zeo ScientifiX (ZEOX) options?

Each option grant carries a $1.67 per share exercise price and a ten-year term. The options are exercisable on a cashless basis through June 10, 2036, subject to the applicable vesting terms described in Zeo ScientifiX’s 2021 Equity Incentive Plan.

How do the Zeo ScientifiX (ZEOX) option grants vest for the CMO?

One grant vests immediately and the other vests on performance milestones. The fully vested grant is exercisable as of the award date, while the performance-based grant becomes exercisable only when specified milestones are achieved, both within the 2021 Equity Incentive Plan framework.

Are the new Zeo ScientifiX (ZEOX) options exercisable on a cashless basis?

Yes, both option grants are exercisable on a cashless basis. This means Shapiro can exercise without paying cash upfront for the full share cost, using a portion of the shares’ value to cover the exercise, consistent with the plan’s terms.

What does antidilutive treatment mean for the Zeo ScientifiX (ZEOX) performance-based options?

The filing states the performance-based options are antidilutive for certain future transactions. Specifically, they are characterized as antidilutive if Zeo ScientifiX undertakes a transaction that issues at least 10% of its fully diluted common stock.